{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:13:40Z","timestamp":1793826820673,"version":"4.6.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T00:00:00Z","timestamp":1667606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T00:00:00Z","timestamp":1667606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002920","name":"Research Grants Council, University Grants Committee","doi-asserted-by":"publisher","award":["Area of Excellence (AoE\/M\/707-18)"],"award-info":[{"award-number":["Area of Excellence (AoE\/M\/707-18)"]}],"id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Circulating thrombospondin-2 (TSP2) levels were associated with the development of heart failure (HF) in recent studies. However, these studies included only a minority of patients with type 2 diabetes, which is associated with an increased HF risk. As hyperglycemia induces TSP2 expression and its tissue expression increases in type 2 diabetes, we investigated the prospective association of circulating TSP2 with incident HF hospitalization (HHF), and its associations with longitudinal changes of echocardiographic parameters in type 2 diabetes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Baseline serum TSP2 levels were measured in 4949 patients with type 2 diabetes to determine its association with incident HHF using multivariable Cox regression analysis. In the echocardiographic study, baseline serum TSP2 levels were measured in another 146 patients with type 2 diabetes but without cardiovascular diseases who underwent detailed transthoracic echocardiography at baseline and after 1 year.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Over a median follow-up of 7.8 years, 330 of 4949 patients (6.7%) developed incident HHF. Baseline serum TSP2 levels were independently associated with the development of HHF (HR 1.31, 95%CI 1.06\u20131.62, p\u2009=\u20090.014) after adjustments for baseline conventional cardiovascular risk factors, atrial fibrillation, estimated glomerular filtration rate, albuminuria and high-sensitivity C-reactive protein level, use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, loop-diuretics, aspirin, insulin, metformin and sodium-glucose co-transporter 2 inhibitors. Moreover, baseline serum TSP2 levels were independently associated with increase in average E\/e\u2019 and left atrial volume index (p\u2009=\u20090.04 and &lt;\u20090.01, respectively).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Serum TSP2 levels were independently associated with both incident HHF and deterioration in diastolic function in type 2 diabetes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Not Applicable<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-022-01646-x","type":"journal-article","created":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T15:04:54Z","timestamp":1667660694000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Prospective associations of circulating thrombospondin-2 level with heart failure hospitalization, left ventricular remodeling and diastolic function in type 2 diabetes"],"prefix":"10.1186","volume":"21","author":[{"given":"CH","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MZ","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DTW","family":"Lui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CHY","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"QW","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SY","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MMA","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WS","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JY","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KH","family":"Yiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KSL","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,5]]},"reference":[{"issue":"6","key":"1646_CR1","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.biocel.2004.01.012","volume":"36","author":"P Bornstein","year":"2004","unstructured":"Bornstein P, Agah A, Kyriakides TR. The role of thrombospondins 1 and 2 in the regulation of cell-matrix interactions, collagen fibril formation, and the response to injury. Int J Biochem Cell Biol. 2004;36(6):1115\u201325.","journal-title":"Int J Biochem Cell Biol"},{"issue":"5","key":"1646_CR2","first-page":"1275","volume":"45","author":"K Zhang","year":"2020","unstructured":"Zhang K, Li M, Yin L, Fu G, Liu Z. Role of thrombospondin1 and thrombospondin2 in cardiovascular diseases (Review). Int J Mol Med. 2020;45(5):1275\u201393.","journal-title":"Int J Mol Med"},{"issue":"4","key":"1646_CR3","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1253\/circj.CJ-13-1221","volume":"78","author":"S Hanatani","year":"2014","unstructured":"Hanatani S, Izumiya Y, Takashio S, Kimura Y, Araki S, Rokutanda T, Tsujita K, Yamamoto E, Tanaka T, Yamamuro M, et al. Circulating thrombospondin-2 reflects disease severity and predicts outcome of heart failure with reduced ejection fraction. Circ J. 2014;78(4):903\u201310.","journal-title":"Circ J"},{"issue":"1","key":"1646_CR4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s00380-014-0571-y","volume":"31","author":"Y Kimura","year":"2016","unstructured":"Kimura Y, Izumiya Y, Hanatani S, Yamamoto E, Kusaka H, Tokitsu T, Takashio S, Sakamoto K, Tsujita K, Tanaka T, et al. High serum levels of thrombospondin-2 correlate with poor prognosis of patients with heart failure with preserved ejection fraction. Heart Vessels. 2016;31(1):52\u20139.","journal-title":"Heart Vessels"},{"issue":"1","key":"1646_CR5","doi-asserted-by":"publisher","first-page":"5830","DOI":"10.1038\/s41467-019-13306-y","volume":"10","author":"A Egerstedt","year":"2019","unstructured":"Egerstedt A, Berntsson J, Smith ML, Gidlof O, Nilsson R, Benson M, Wells QS, Celik S, Lejonberg C, Farrell L, et al. Profiling of the plasma proteome across different stages of human heart failure. Nat Commun. 2019;10(1):5830.","journal-title":"Nat Commun"},{"issue":"17","key":"1646_CR6","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/j.jacc.2019.01.074","volume":"73","author":"QS Wells","year":"2019","unstructured":"Wells QS, Gupta DK, Smith JG, Collins SP, Storrow AB, Ferguson J, Smith ML, Pulley JM, Collier S, Wang X, et al. Accelerating biomarker discovery through electronic health records, automated biobanking, and proteomics. J Am Coll Cardiol. 2019;73(17):2195\u2013205.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"1646_CR7","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.cardfail.2019.05.007","volume":"25","author":"SM Dunlay","year":"2019","unstructured":"Dunlay SM, Givertz MM, Aguilar D, Allen LA, Chan M, Desai AS, Deswal A, Dickson VV, Kosiborod MN, Lekavich CL, et al. Type 2 diabetes mellitus and heart failure, a scientific statement from the American heart association and heart failure society of America. J Card Fail. 2019;25(8):584\u2013619.","journal-title":"J Card Fail"},{"key":"1646_CR8","doi-asserted-by":"crossref","unstructured":"Kristensen SL, Preiss D, Jhund PS, Squire I, Cardoso JS, Merkely B, Martinez F, Starling RC, Desai AS, Lefkowitz MP, et al. Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI With ACEI to determine impact on global mortality and morbidity in heart failure trial. Circ Heart Fail 2016, 9(1).","DOI":"10.1161\/CIRCHEARTFAILURE.115.002560"},{"issue":"11","key":"1646_CR9","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.2337\/dc07-0717","volume":"30","author":"E Erdmann","year":"2007","unstructured":"Erdmann E, Charbonnel B, Wilcox RG, Skene AM, Massi-Benedetti M, Yates J, Tan M, Spanheimer R, Standl E, Dormandy JA, et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care. 2007;30(11):2773\u20138.","journal-title":"Diabetes Care"},{"issue":"1","key":"1646_CR10","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12933-021-01430-3","volume":"20","author":"D Giugliano","year":"2021","unstructured":"Giugliano D, Longo M, Scappaticcio L, Bellastella G, Maiorino MI, Esposito K. SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs. Cardiovasc Diabetol. 2021;20(1):236.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"1646_CR11","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1161\/ATVBAHA.110.219675","volume":"31","author":"P Raman","year":"2011","unstructured":"Raman P, Harry C, Weber M, Krukovets I, Stenina OI. A novel transcriptional mechanism of cell type-specific regulation of vascular gene expression by glucose. Arterioscler Thromb Vasc Biol. 2011;31(3):634\u201342.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"1646_CR12","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1161\/ATVBAHA.113.301609","volume":"33","author":"ON Bae","year":"2013","unstructured":"Bae ON, Wang JM, Baek SH, Wang Q, Yuan H, Chen AF. Oxidative stress-mediated thrombospondin-2 upregulation impairs bone marrow-derived angiogenic cell function in diabetes mellitus. Arterioscler Thromb Vasc Biol. 2013;33(8):1920\u20137.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1646_CR13","doi-asserted-by":"crossref","unstructured":"Kunkemoeller B, Bancroft T, Xing H, Morris AH, Luciano AK, Wu J, Fernandez-Hernando C, Kyriakides TR: Elevated Thrombospondin-2 contributes to delayed wound healing in diabetes. Diabetes 2019.","DOI":"10.1096\/fasebj.2018.32.1_supplement.414.3"},{"issue":"22","key":"1646_CR14","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"7","key":"1646_CR15","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"4","key":"1646_CR16","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"21","key":"1646_CR17","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlavek J, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"15","key":"1646_CR18","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413\u201324.","journal-title":"N Engl J Med"},{"key":"1646_CR19","doi-asserted-by":"crossref","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021.","DOI":"10.1056\/NEJMoa2107038"},{"issue":"1","key":"1646_CR20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s00125-018-4742-8","volume":"62","author":"CH Lee","year":"2019","unstructured":"Lee CH, Cheung CYY, Woo YC, Lui DTW, Yuen MMA, Fong CHY, Chow WS, Xu A, Lam KSL. Prospective associations of circulating adipocyte fatty acid-binding protein levels with risks of renal outcomes and mortality in type 2 diabetes. Diabetologia. 2019;62(1):169\u201377.","journal-title":"Diabetologia"},{"issue":"3","key":"1646_CR21","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.jdiacomp.2014.01.003","volume":"28","author":"Y Chen","year":"2014","unstructured":"Chen Y, Zhao CT, Zhen Z, Wong A, Tse HF, Yiu KH. Association of myocardial dysfunction with vitamin D deficiency in patients with type 2 diabetes mellitus. J Diabetes Complicat. 2014;28(3):286\u201390.","journal-title":"J Diabetes Complicat"},{"issue":"1","key":"1646_CR22","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12933-020-01167-5","volume":"19","author":"MZ Wu","year":"2020","unstructured":"Wu MZ, Lee CH, Chen Y, Yu SY, Yu YJ, Ren QW, Fong HC, Wong PF, Tse HF, Lam SK, et al. Association between adipocyte fatty acid-binding protein with left ventricular remodelling and diastolic function in type 2 diabetes: a prospective echocardiography study. Cardiovasc Diabetol. 2020;19(1):197.","journal-title":"Cardiovasc Diabetol"},{"issue":"9","key":"1646_CR23","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"key":"1646_CR24","doi-asserted-by":"crossref","unstructured":"Chapter 2. Definition, identification, and prediction of CKD progression. Kidney International Supplements 2013(3):63\u201372.","DOI":"10.1038\/kisup.2012.65"},{"key":"1646_CR25","unstructured":"Methodology WCCfDS: Anatomical Therapeutic Chemical (ATC) \/ Defined Daily Dose (DDD) index on sodium-glucose co-transporter 2 inhibitors. 2019."},{"key":"1646_CR26","doi-asserted-by":"crossref","unstructured":"D. S: Chi-squared goodness-of-fit tests for the proportional hazards regression model. Biometrika 1980, 67(1):145\u2013153.","DOI":"10.1093\/biomet\/67.1.145"},{"issue":"10","key":"1646_CR27","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1002\/ejhf.2291","volume":"23","author":"KP Kresoja","year":"2021","unstructured":"Kresoja KP, Rommel KP, Wachter R, Henger S, Besler C, Kloting N, Schnelle M, Hoffmann A, Buttner P, Ceglarek U, et al. Proteomics to improve phenotyping in obese patients with heart failure with preserved ejection fraction. Eur J Heart Fail. 2021;23(10):1633\u201344.","journal-title":"Eur J Heart Fail"},{"issue":"15","key":"1646_CR28","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1161\/CIRCULATIONAHA.119.045158","volume":"142","author":"MY Chan","year":"2020","unstructured":"Chan MY, Efthymios M, Tan SH, Pickering JW, Troughton R, Pemberton C, Ho HH, Prabath JF, Drum CL, Ling LH, et al. Prioritizing candidates of post-myocardial infarction heart failure using plasma proteomics and single-cell transcriptomics. Circulation. 2020;142(15):1408\u201321.","journal-title":"Circulation"},{"issue":"3","key":"1646_CR29","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0002-9440(10)64243-5","volume":"161","author":"A Agah","year":"2002","unstructured":"Agah A, Kyriakides TR, Lawler J, Bornstein P. The lack of thrombospondin-1 (TSP1) dictates the course of wound healing in double-TSP1\/TSP2-null mice. Am J Pathol. 2002;161(3):831\u20139.","journal-title":"Am J Pathol"},{"issue":"1","key":"1646_CR30","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.carpath.2012.03.005","volume":"22","author":"H Reinecke","year":"2013","unstructured":"Reinecke H, Robey TE, Mignone JL, Muskheli V, Bornstein P, Murry CE. Lack of thrombospondin-2 reduces fibrosis and increases vascularity around cardiac cell grafts. Cardiovasc Pathol. 2013;22(1):91\u20135.","journal-title":"Cardiovasc Pathol"},{"issue":"5","key":"1646_CR31","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1161\/01.RES.0000141019.20332.3e","volume":"95","author":"B Schroen","year":"2004","unstructured":"Schroen B, Heymans S, Sharma U, Blankesteijn WM, Pokharel S, Cleutjens JP, Porter JG, Evelo CT, Duisters R, van Leeuwen RE, et al. Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure-prone cardiac hypertrophy. Circ Res. 2004;95(5):515\u201322.","journal-title":"Circ Res"},{"issue":"16","key":"1646_CR32","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1161\/CIRCULATIONAHA.109.863266","volume":"120","author":"M Swinnen","year":"2009","unstructured":"Swinnen M, Vanhoutte D, Van Almen GC, Hamdani N, Schellings MW, D\u2019Hooge J, Van der Velden J, Weaver MS, Sage EH, Bornstein P, et al. Absence of thrombospondin-2 causes age-related dilated cardiomyopathy. Circulation. 2009;120(16):1585\u201397.","journal-title":"Circulation"},{"issue":"3","key":"1646_CR33","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.yjmcc.2011.05.010","volume":"51","author":"GC van Almen","year":"2011","unstructured":"van Almen GC, Swinnen M, Carai P, Verhesen W, Cleutjens JP, D\u2019Hooge J, Verheyen FK, Pinto YM, Schroen B, Carmeliet P, et al. Absence of thrombospondin-2 increases cardiomyocyte damage and matrix disruption in doxorubicin-induced cardiomyopathy. J Mol Cell Cardiol. 2011;51(3):318\u201328.","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"1646_CR34","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/cvr\/cvs077","volume":"94","author":"AP Papageorgiou","year":"2012","unstructured":"Papageorgiou AP, Swinnen M, Vanhoutte D, VandenDriessche T, Chuah M, Lindner D, Verhesen W, de Vries B, D\u2019Hooge J, Lutgens E, et al. Thrombospondin-2 prevents cardiac injury and dysfunction in viral myocarditis through the activation of regulatory T-cells. Cardiovasc Res. 2012;94(1):115\u201324.","journal-title":"Cardiovasc Res"},{"issue":"10138","key":"1646_CR35","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1016\/S0140-6736(18)30314-3","volume":"391","author":"EW Gregg","year":"2018","unstructured":"Gregg EW, Cheng YJ, Srinivasan M, Lin J, Geiss LS, Albright AL, Imperatore G. Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data. Lancet. 2018;391(10138):2430\u201340.","journal-title":"Lancet"},{"issue":"2","key":"1646_CR36","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255\u2013323.","journal-title":"Eur Heart J"},{"issue":"24","key":"1646_CR37","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"2","key":"1646_CR38","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Inzucchi SE, Kosiborod MN, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384(2):129\u201339.","journal-title":"N Engl J Med"},{"issue":"2","key":"1646_CR39","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117\u201328.","journal-title":"N Engl J Med"},{"issue":"16","key":"1646_CR40","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361.","journal-title":"N Engl J Med"},{"key":"1646_CR41","doi-asserted-by":"crossref","unstructured":"Lee CH, Seto WK, Lui DT, Fong CH, Wan HY, Cheung CY, Chow WS, Woo YC, Yuen MF, Xu A, et al. Circulating Thrombospondin-2 as a novel fibrosis biomarker of nonalcoholic fatty liver disease in type 2 diabetes. Diabetes Care 2021.","DOI":"10.2337\/figshare.14673267.v1"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-022-01646-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-022-01646-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-022-01646-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T15:05:06Z","timestamp":1667660706000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-022-01646-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,5]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1646"],"URL":"https:\/\/doi.org\/10.1186\/s12933-022-01646-x","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,5]]},"assertion":[{"value":"16 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocols were approved by the Institutional Review Board of the University of Hong Kong \/ Hospital Authority Hong Kong West Cluster (Ref: UW 07-378 and UW 11\u2013121, respectively). Written informed consent was obtained from all recruited participants prior to any study related procedures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have approved the manuscript and agreed with its publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"K.S.L. is an advisory board member of Merck Sharp and Dohme. C.H.L. received speaker\u2019s fees from AstraZeneca, Bayer and Sanofi Aventis. The remaining authors have no conflict of interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"231"}}